Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

Summary

This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a total duration of up to 24 weeks participation.

Timeline

Start

2022-05-27

Primary completion

2027-03-01

Completion

2027-03-01

Drugs

Indications